Beijing Biostar Pharmaceuticals Co., Ltd. (BIOSTAR PHARM-B) reported a substantial expansion of its Hong Kong–listed share capital for the month ended 31 March 2026, driven by the conversion of all remaining unlisted shares into H shares.

Key developments

1. Full circulation achieved • On 30 March 2026, 147.87 million unlisted ordinary shares were converted into H shares, finalising the company’s full-circulation process. • Following the conversion, the number of authorised/registered H shares rose 68.23% from 216.72 million to 364.59 million, equal to the new issued share total.

2. Issued share capital dynamics • H shares in issue (excluding treasury shares) climbed from 216.72 million to 364.59 million during March—an increase of 147.87 million shares. • The company holds no treasury shares.

3. Public float intact • BIOSTAR PHARM-B confirmed compliance with the Main Board’s minimum 25% public-float requirement as at 31 March 2026.

4. No dilutive instruments outstanding • The issuer reported no share option schemes, warrants, convertibles or other equity-linked instruments during the period.

Implications

The shift of 147.87 million previously unlisted shares into the Hong Kong market enhances BIOSTAR PHARM-B’s tradable float and could improve liquidity without altering the total registered capital of RMB 364.59 million. The absence of outstanding equity-linked securities indicates a straightforward capital structure post-conversion.